FDA Approves GORE HELEX Septal Occluder for Treatment of Atrial Septal Defect.Innovative, Less Invasive Treatment Option for Congenital Heart Defect Noun 1. congenital heart defect - a birth defect involving the heart birth defect, congenital abnormality, congenital anomaly, congenital defect, congenital disorder - a defect that is present at birth FLAGSTAFF, Ariz. -- W. L. Gore & Associates (Gore) today announced that the U.S. Food & Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) granted approval for the GORE HELEX HELEX Helicopter(ed) Exercise Septal septal /sep·tal/ (sep´tal) pertaining to a septum. sep·tal adj. Of or relating to a septum or septa. Occluder with modified catheter delivery system indicated for the transcatheter closure of atrial septal defect Atrial Septal Defect Definition An atrial septal defect is an abnormal opening in the wall separating the left and right upper chambers (atria) of the heart. (ASD ASD abbr. atrial septal defect ASD Atrial septal defect, see there ). An ASD is a congenital heart defect that affects thousands of patients every year. The GORE HELEX Septal Occluder is a permanently implanted prosthesis and the first device of its kind to use ePTFE, a biocompatible material that allows tissue ingrowth ingrowth /in·growth/ (-groth) an inward growth; something that grows inward or into. in·growth n. Something that grows inward or into a part of the body. , to seal the defect. The recently approved catheter-based delivery system allows for easier device deployment via standard femoral venous access, bringing the GORE HELEX Septal Occluder to the forefront of non-surgical ASD repair. An ASD is an abnormal hole in the wall between the upper chambers of the heart, which allows blood to improperly flow from the left side of the heart to the right, forcing the right side of the heart and lungs to overexert o·ver·ex·ert tr.v. o·ver·ex·ert·ed, o·ver·ex·ert·ing, o·ver·ex·erts To exert (oneself) too much; overtax. o to compensate for the problem. Left untreated, an ASD can cause the heart to enlarge, or weaken, leaving the patient at risk for serious conditions like atrial fibrillation, pulmonary hypertension, heart failure or stroke. The defect is most often treated in pediatric patients. "In treating such a delicate area of the heart, particularly in small children, interventional cardiologists need to be confident that treatment will be effective for the long term," said Dr. Alexander Javois, The Heart Institute for Children, Advocate Hope Children's Hospital, Oak Lawn, Illinois Oak Lawn is a village in Cook County, Illinois, USA. As of the 2000 census, the village had a total population of 55,245. Oak Lawn is a suburb of the city of Chicago, located southwest of the city. . "Percutaneous ASD closure is successful in the very young patient using the GORE HELEX Septal Occluder. Its design and conformity allows tissue to incorporate the device easily so that it becomes part of the heart's anatomy, sealing the ASD successfully and improving, even normalizing, the patient's heart function without open heart surgery." The GORE HELEX Septal Occluder is composed of ePTFE patch material supported by a single nitinol wire frame that bridges and eventually occludes the septal defect to stop the shunting of blood between the atria. Over the course of several weeks to months, cells begin to infiltrate and grow over the ePTFE membrane, resulting in successful closure of the defect. "Open heart surgery is no longer the only available option to correct an ASD in young children and in patients with complicating health factors. Interventional cardiologists can close the defect permanently through a minimally invasive procedure Minimally invasive surgical procedures avoid open invasive surgery in favor of closed or local surgery with less trauma. These procedures involve use of laparoscopic devices and remote-control manipulation of instruments with indirect observation of the surgical field through an with a shorter recovery time," said Peter Zeller, PhD, Gore Product Specialist. "The GORE HELEX Septal Occluder has been used in thousands of successful implants worldwide, and we are excited that the device is now available to physicians so that they can treat many more patients in the U.S." Strong clinical data over the course of several years has demonstrated the efficacy of the GORE HELEX Septal Occluder in treating ASDs. The GORE HELEX Septal Occluder has been used successfully in thousands of implants and has been available in Europe, Latin America and Australia, and under an Investigational Device Exemption An Investigational Device Exemption (IDE) allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval (PMA) application or a Premarket Notification [510(k)] submission to Food and (IDE) in the US. The GORE HELEX Device with the original delivery system was previously approved in the United States in August 2006. ABOUT W. L. GORE & ASSOCIATES The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for three decades. During that time, more than 25 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair and sutures for use in vascular, cardiac and general surgery. Gore was recently named the tenth best company to work for in America by Fortune. For more information, visit http://www.goremedical.com/helex. Products listed may not be available in all markets pending regulatory clearance. GORE and HELEX are trademarks of W. L. Gore & Associates. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion